Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Meta-Analysis Comparing the Safety and Efficacy of Dual Versus Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation

Meta-Analysis Comparing the Safety and Efficacy of Dual Versus Single Antiplatelet Therapy After... American Journal of Cardiovascular Drugs (2021) 21:373–376 https://doi.org/10.1007/s40256-021-00466-w RESEARCH LE T TER Meta‑Analysis Comparing the Safety and Efficacy of Dual Versus Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation 1 1 2 3 Izza Shahid  · Muhammad Abdullah Nizam  · Muhammad Shariq Usman  · Muhammad Shahzeb Khan  · 4 5 Marat Fudim  · Erin D. Michos Accepted: 28 January 2021 / Published online: 26 February 2021 © The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021 Dear Editor, “TAVR,” “dual antiplatelet therapy,” “single antiplatelet therapy,” “aspirin,” “clopidogrel,” “antiplatelet,” “antithrom- Current expert consensus guidelines recommend dual anti- botic,” and “P2Y receptor antagonist.” Studies were included platelet therapy (DAPT) with aspirin and clopidogrel for if they (1) were RCTs, (2) included patients undergoing 3–6 months after transcatheter aortic valve implantation TAVI, and (3) evaluated direct comparison between DAPT (TAVI) [1]. This recommendation, however, is based primar- (aspirin and clopidogrel) and SAPT (only aspirin) after ily on data from small observational studies, which suggest TAVI. Outcomes of interest included (1) all-cause mor- improved mortality with DAPT [2]. The recent Antiplate- tality, (2) disabling stroke, (3) myocardial infarction, (4) let Therapy for Patients Undergoing Transcatheter Aortic major bleeding, and (5) life-threatening bleeding. The two Valve Implantation (POPular-TAVI) trial highlighted that http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Meta-Analysis Comparing the Safety and Efficacy of Dual Versus Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/meta-analysis-comparing-the-safety-and-efficacy-of-dual-versus-single-hrGV49WSo7
Publisher
Springer Journals
Copyright
Copyright © The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-021-00466-w
Publisher site
See Article on Publisher Site

Abstract

American Journal of Cardiovascular Drugs (2021) 21:373–376 https://doi.org/10.1007/s40256-021-00466-w RESEARCH LE T TER Meta‑Analysis Comparing the Safety and Efficacy of Dual Versus Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation 1 1 2 3 Izza Shahid  · Muhammad Abdullah Nizam  · Muhammad Shariq Usman  · Muhammad Shahzeb Khan  · 4 5 Marat Fudim  · Erin D. Michos Accepted: 28 January 2021 / Published online: 26 February 2021 © The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021 Dear Editor, “TAVR,” “dual antiplatelet therapy,” “single antiplatelet therapy,” “aspirin,” “clopidogrel,” “antiplatelet,” “antithrom- Current expert consensus guidelines recommend dual anti- botic,” and “P2Y receptor antagonist.” Studies were included platelet therapy (DAPT) with aspirin and clopidogrel for if they (1) were RCTs, (2) included patients undergoing 3–6 months after transcatheter aortic valve implantation TAVI, and (3) evaluated direct comparison between DAPT (TAVI) [1]. This recommendation, however, is based primar- (aspirin and clopidogrel) and SAPT (only aspirin) after ily on data from small observational studies, which suggest TAVI. Outcomes of interest included (1) all-cause mor- improved mortality with DAPT [2]. The recent Antiplate- tality, (2) disabling stroke, (3) myocardial infarction, (4) let Therapy for Patients Undergoing Transcatheter Aortic major bleeding, and (5) life-threatening bleeding. The two Valve Implantation (POPular-TAVI) trial highlighted that

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: Feb 26, 2021

There are no references for this article.